Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

Effect of patient-specific factors on weekly warfarin dose

Authors Heather P Whitley, Joli D Fermo, Elinor CG Chumney, Walter Adam Brzezinski

Published 15 July 2007 Volume 2007:3(3) Pages 499—504

Heather P Whitley1, Joli D Fermo2, Elinor CG Chumney2,3, Walter Adam Brzezinski3

1Auburn University Harrison School of Pharmacy, Department of Pharmacy Practice and The University of Alabama School of Medicine, Tuscaloosa, Department of Community and Rural Medicine, Tuscaloosa, AL USA; 2South Carolina College of Pharmacy, Department of Pharmacy and Clinical Sciences, Charleston, SC USA; 3Medical University of South Carolina, College of Medicine, Charleston, SC USA

Abstract

Objective: To determine the influence of various patient-specific factors, use of concomitant medications, and weekly vitamin K intake on total weekly warfarin maintenance dose (TWD).

Methods: Information collected, via retrospective chart review, included TWD, general demographics, vitamin K consumption, target INR range, use of alcohol, tobacco, and cytochrome P450 (CYP)-inducing medications, and concomitant medications and diseases.

Results: The majority of patients (n = 131) were Caucasian (71%), with more females (55%) than males. Use of CYP-inducing medications resulted in the largest correlation coefficient (r = 0.30). The sample was divided into high warfarin dose (TWD ≥ 50 mg) and low warfarin dose (TWD ≤ 25 mg) patient populations to discern areas where the two populations differed. Age and amiodarone use were the only statistically significant differences between the two groups, with high dose patients tending to be younger and to use less amiodarone. Age and CYP-inducing medications were found to be the only statistically significant predictors of TWD in the regression analysis. The TWD was 2.4 mg less for each additional decade of patient age. The coefficient on CYP-inducing medications indicates that the concomitant use of a CYP inducer is associated with an increase in TWD of 17.2 additional milligrams, adjusting for all other variables in the model.

Conclusion: We found concomitant use of CYP inducer, age, height, and ethnicity to have the greatest influence on TWD. Positive relationships were found between TWD and the use of CYP450 inducer, height, and African American ethnicity. Although it did appear that women required a lower TWD than men, this factor contributed mildly. Further studies with a greater sample size may more precisely predict the effect of patient-specific factors on TWD, thus uncovering additional relationships.

Keywords: anticoagulation, survey, vitamin K, warfarin, CYP450 inducers

Download Article [PDF] 

Readers of this article also read:

Chloramphenicol encapsulated in poly-ε-caprolactone–pluronic composite: nanoparticles for treatment of MRSA-infected burn wounds

Kalita S, Devi B, Kandimalla R, Sharma KK, Sharma A, Kalita K, Kataki AC, Kotoky J

International Journal of Nanomedicine 2015, 10:2971-2984

Published Date: 15 April 2015

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency

Burgess BL, He Y, Baker MM, Luo B, Carroll SF, Forte TM, Oda MN

International Journal of Nanomedicine 2013, 8:4733-4743

Published Date: 12 December 2013

Selective laser sintering fabrication of nano-hydroxyapatite/poly-ε-caprolactone scaffolds for bone tissue engineering applications

Xia Y, Zhou PY, Cheng XS, Xie Y, Liang C, Li C, Xu SG

International Journal of Nanomedicine 2013, 8:4197-4213

Published Date: 1 November 2013

BAK additive influence on results

Shah RD, Lemon TI, Yarrow-Jenkins A

Clinical Ophthalmology 2013, 7:1081-1082

Published Date: 6 June 2013

Diagnosis with ECG-gated MDCT of floating thrombus in aortic arch in a patient with type-A dissection

Domenico Lumia, Gianpaolo Carrafiello, Domenico Laganà, Andrea Musazzi, Andrea Giorgianni, et al

Vascular Health and Risk Management 2008, 4:735-739

Published Date: 6 June 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007